Marie-Léa Gauci

Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Marie-Léa Gauci, Émilie Lanoy, Stéphane Champiat et al. · Clinical Cancer Research · 2018 · 140 citations

Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab

Marie-Léa Gauci, Barouyr Baroudjian, Pauline Laly et al. · Seminars in Arthritis and Rheumatism · 2017 · 49 citations

Rheumatology, Autoimmune Disease, Pathogenesis +7

Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study

Marie-Léa Gauci, Philippe Boudou, Barouyr Baroudjian et al. · Cancer Immunology Immunotherapy · 2018 · 35 citations · Full text

Retrospective Study, Type 1, Cancer Immunosurveillance +9

Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal

Marie-Léa Gauci, Barouyr Baroudjian, Ulysse Bédérède et al. · Clinics and Research in Hepatology and Gastroenterology · 2020 · 32 citations

Immunology, Hepatitis B, Pathology +16

Successful treatment of type II pityriasis rubra pilaris with secukinumab

Marie-Léa Gauci, M. Jachiet, J. Gottlieb et al. · JAAD Case Reports · 2016 · 30 citations · Full text

Inflammation, Pityriasis Rubra Pilaris, Autoimmune Disease +12